PON1 and benign prostatic hyperplasia: The present study compared paraoxonase (PON1, PON3), PON1/HDL, triglyceride, HDL, LDL, and MDA levels in patients with PCa among individuals with BPH, undergoing RARLP, with no biochemical recurrence and a control group.